Related Experiment Video
Updated: Aug 18, 2026
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
Intratumoral aromatase model: the effects of letrozole (CGS 20267)
1Department of Pharmacology and Experimental Therapeutics, Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore 21201, USA.
Abstract:
An intratumoral aromatase model in the ovariectomized nude mouse was developed which simulated the hormone responsive postmenopausal breast cancer patient. MCF-7, human breast cancer cells transfected with the aromatase gene, inoculated into ovariectomized nude mice are able to synthesize sufficient estrogens to enhance cell proliferation and the development of tumors. These tumors are responsive to both antiestrogens and aromatase inhibitors. However, letrozole was found to be more effective than tamoxifen and caused tumor regression, a result not previously noted in nude mice with endocrine treatments. When the aromatase inhibitors were combined with tamoxifen, tumor growth was suppressed to about the same extent as treatment with the aromatase inhibitors alone. Thus, there was no additive or synergistic effects of combining tamoxifen with aromatase inhibitors. These results suggest that letrozole has the potential to be more effective than tamoxifen for achieving greater reduction in estrogenic effects on tumors and uterus in postmenopausal breast cancer patients. In addition, sequential treatment with these agents is likely to be more beneficial to the patient in terms of longer response to treatment.
Insights
This study developed a novel aromatase model for postmenopausal breast cancer. Letrozole demonstrated superior efficacy over tamoxifen, inducing tumor regression in mice.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Postmenopausal breast cancer is often hormone-dependent.
- Estrogen synthesis via aromatase plays a key role in tumor growth.
- Current treatments include antiestrogens and aromatase inhibitors.
Purpose of the Study:
- To develop an intratumoral aromatase model simulating postmenopausal breast cancer.
- To compare the efficacy of letrozole and tamoxifen in this model.
- To investigate the effects of combination therapy.
Main Methods:
- Developed an intratumoral aromatase model using MCF-7 cells in ovariectomized nude mice.
- Administered letrozole, tamoxifen, and combination therapies.
- Monitored tumor proliferation, regression, and estrogenic effects.
Main Results:
- The model successfully simulated hormone-responsive breast cancer.
- Letrozole induced significant tumor regression, outperforming tamoxifen.
- Combination therapy showed no additive or synergistic effects compared to aromatase inhibitors alone.
Conclusions:
- Letrozole shows greater potential than tamoxifen for reducing estrogenic effects in postmenopausal breast cancer.
- Sequential treatment with letrozole and tamoxifen may offer prolonged therapeutic response.
